What is Liquidia?
Liquidia Corporation, through its subsidiary Liquidia Technologies, Inc., is a late-stage clinical biopharmaceutical company dedicated to advancing patient care via its proprietary PRINT® technology. This particle engineering platform allows for the precise creation of uniform drug particles, aiming to enhance the safety, efficacy, and overall performance of various therapies. The company's current focus is on two key product candidates: LIQ861 for pulmonary arterial hypertension (PAH) and LIQ865 for post-operative pain management. Headquartered in Research Triangle Park, NC, Liquidia is strategically positioned to leverage its technological advancements in a competitive market.
How much funding has Liquidia raised?
Liquidia has raised a total of $233M across 7 funding rounds:
Series A
$6M
Series B
$16M
Series C
$25M
Series D
$25.5M
Debt
$20.5M
Debt
$40M
Debt
$100M
Series A (2006): $6M with participation from Wakefield Group, Firelake Capital, Siemens, and Next47
Series B (2007): $16M led by Firelake Capital, Wakefield Group, and New Enterprise Associates
Series C (2010): $25M supported by Firelake Capital, Canaan Partners, Pappas Capital, and New Enterprise Associates
Series D (2018): $25.5M featuring Xeraya Capital, Canaan Partners, Morningside Group, and New Enterprise Associates
Debt (2021): $20.5M backed by Silicon Valley Bank
Debt (2022): $40M with participation from Silicon Valley Bank
Debt (2025): $100M, investors not publicly disclosed
Key Investors in Liquidia
Silicon Valley Bank
Silicon Valley Bank is a financial institution offering a comprehensive suite of banking and financial services, with a significant presence in supporting technology and healthcare companies. Their involvement suggests a strong belief in Liquidia's financial viability and growth prospects.
Firelake Capital
Firelake Strategic Technology Fund focuses on investing in groundbreaking proprietary technologies within sectors like energy, communications, and materials. Their participation indicates an interest in Liquidia's innovative PRINT® technology and its potential for market disruption.
Canaan Partners
Canaan is an early-stage venture capital firm with a strong track record in both technology and healthcare, investing from seed through growth stages. Their backing of Liquidia highlights the company's potential in the biopharma and digital health sectors.
What's next for Liquidia?
The recent major strategic investment signals a pivotal phase for Liquidia Corporation, likely enabling the company to advance its clinical trials, expand its manufacturing capabilities, and prepare for broader market entry. This capital will be instrumental in navigating the complex regulatory landscape and scaling operations to meet the demand for its novel therapeutic solutions. The company's trajectory suggests a strong focus on achieving key developmental milestones and securing commercial partnerships to maximize the impact of its PRINT® technology.
See full Liquidia company page
